With the rise of the oncology therapy market within Japan-Asia Pacific (JAPAC) alongside new scientific knowledge and technologies, emerging biopharma and biotech companies must have an enhanced understanding of a rapidly evolving treatment paradigm that is increasingly nuanced, complex, and patient-directed.

Conducting clinical trials in hematologic malignancies requires deep knowledge of scientific and operational pathways to develop effective personalized treatments. Engaging a partner that has knowledgeable, well-trained and widely-connected teams can lay the ground work to deliver on unique endpoints, study designs and data management.

In this white paper, we examine the considerations in successfully conducting hematologic oncology clinical trials and how sponsors can be supported in bringing their innovative therapies to market. Download the paper to find out more.